Clinical Trials Browser

Active not recruiting × Breast Neoplasms × Magnetic Resonance Spectroscopy × Clear all

Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04316117 2026-03-23

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Phase 2 Active not recruiting

138 enrolled

Breast

Breast Neoplasms

NCT03941730 2026-03-05

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Active not recruiting

8 enrolled 9 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02226276 2026-02-13

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Phase NA Active not recruiting

10 enrolled 8 charts

Breast

Breast Neoplasms

NCT04692103 2026-01-22

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Phase 2 Active not recruiting

2 enrolled 8 charts

Breast

Breast Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

18 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT02115282 2025-12-18

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Phase 3 Active not recruiting

608 enrolled 18 charts

Breast

Breast Neoplasms

NCT05226663 2025-12-15

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Phase 2 Active not recruiting

36 enrolled

Breast

Breast Neoplasms

NCT02849496 2025-11-24

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Phase 2 Active not recruiting

81 enrolled

Breast

Breast Neoplasms

NCT01251874 2025-11-21

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Phase 1 Active not recruiting

44 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01093612 2025-11-14

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Phase NA Active not recruiting

18 enrolled 6 charts

Breast

Breast Neoplasms

NCT02293954 2025-11-14

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Phase NA Active not recruiting

20 enrolled 8 charts

BreastGastrointestinalThoracic

Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms, Carcinoma, Medullary

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Phase 2 Active not recruiting

18 enrolled 8 charts

Breast

Breast Neoplasms

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04147494 2025-08-12

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Phase EARLY_PHASE1 Active not recruiting

29 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT01937117 2025-07-01

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Phase 2 Active not recruiting

88 enrolled 15 charts

Breast

Breast Neoplasms

Clinical Trials

18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer